Feb 13, 2020 (Heraldkeepers) — Blood clotting factors are proteins or enzymes that control bleeding. Blood clotting or blood coagulation is a process in which the blood gets converted into solid clots during the breakdown of blood vessels. Clotting can prevent death from bleeding and moreover, restrict the entry of bacteria and viruses into the body. Deficiency of the blood clotting factors can cause various blood clotting diseases, such as haemophilia and von willebrand disease (VWD). According to the Centre for Disease Control and Prevention (CDC), around 20,000 males were reported to be suffering from Haemophilia in the U.S. in 2017.
Get the sample copy of this business report: https://www.coherentmarketinsights.com/insight/request-sample/1301
Approval of novel drugs in key regional markets, such as North America and Europe, is expected to boost the global blood clotting factors market development
In November 2017, the U.S. FDA approved Hemlibra (Emicizumab-kxwh) developed by Roche AG, for the treatment of Haemophilia A patient with inhibitors. This was the first approval by FDA in about 20 years to treat people with hemophilia A with inhibitors. Moreover, the FDA approved Adynovate of Shire Plc for the treatment of hemophilia A patients. The drug has also been approved for use in surgical setting for both category of patients, adult and pediatric. Furthermore, in January 2018, the drug (Adynovate) was granted marketing authorization in the European Union (EU). In the EU, the drug got approval for adults and adolescents suffering from Hemophilia A. These approvals provided an alternate treatment option for patients suffering from hemophilia. Introduction of these drugs into the market is said to have fueled the growth of the blood clotting factors market in the recent past.
Global Blood Clotting Factors Market Taxonomy
By Product Type
Von Willebrand Factor
Anti-Inhibitor Coagulant Complex
Von willebrand disease (VWD)
Other bleeding disorders
By Distribution channel
North America is expected to hold a dominant position in the global blood clotting factors market
Haemophilia is a rare disorder affecting very small fraction of population across the globe. Pharmaceutical companies invest less amount on development of such drugs due to low return on investment. However, FDA has recognized this fact and has formulated favorable policy to motivate companies to invest in this area. Orphan Drug Act that applies to company operating in this area provides three special incentives i.e. 7 years exclusivity period, tax credit and waiver of prescription drug user fees. Due to such policy, the company has invested in rare disease research which has led to development of products such as Hemlibra (Emicizumab-kxwh), Adynovate and Others. Furthermore, increasing awareness regarding rare disease in developed economies such as U.S. and Canada has resulted in high number of patients receiving treatment. Owing to the abovementioned factors, North America has led the global market in terms of market share and is expected to retain its position over the forecast period. However, Asia Pacific is expected to witness robust market growth due to the improved ratio of patients suffering from diseases and patients receiving treatments. Availability of generic products, at much lower price compared to branded product, in the market is expected to fuel growth of the Asia Pacific blood clotting factors market.
Buy this premium business report: https://www.coherentmarketinsights.com/insight/buy-now/1301
Significant Market Players
The key contenders operating in the global blood clotting factors market include Shire Plc, Baxter International Inc., Grifols International SA, Roche AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG, Biogen Idec, and Kedrion S.P.A.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Visit Our Blog: https://blog.coherentmarketinsights.com